Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13802754 | 0.88 | CTSK (0.36) | CTSKCTSSTRPA1CA2CA1 | |
| SCHEMBL13802743 | 0.87 | CTSS (0.49) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL13802748 | 0.87 | CTSS (0.49) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL13802749 | 0.85 | CTSS (0.39) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL4162885 | 0.84 | IDO1 (0.38) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL13802659 | 0.81 | KLK5 (0.45) | CTSKCTSSIDO1 | |
| SCHEMBL14131867 | 0.81 | KLK5 (0.45) | CTSKCTSSIDO1 | |
| SCHEMBL4162914 | 0.80 | CTSL (0.48) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL4162891 | 0.80 | CTSK (0.41) | CTSKCTSSTRPA1CA2CA1 | |
| SCHEMBL4174487 | 0.80 | CTSK (0.46) | CTSKCTSSCA2CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1529042-B1 | ARYLAMIDES | INTERMED DISCOVERY GMBH (DE) | 2013-02-20 | — | — | EP | disclosed |
| US-20090149528-A1 | Cinnamic acid amides | BAYER HEALTHCARE AG (DE) | 2009-06-11 | — | — | US | disclosed |
| US-20090149528-A1 | Cinnamic acid amides | BAYER HEALTHCARE AG (DE) | 2009-06-11 | — | — | US | disclosed |
| US-20090149528-A1 | Cinnamic acid amides | BAYER HEALTHCARE AG (DE) | 2009-06-11 | — | — | US | disclosed |
| US-7544709-B2 | Bactericides; (S)-3-(3-Butylureido)-N-{(S)-2-methyl-1-[1-((3R,4S)-4-methyl-2,5-dioxopyrrolidin-3-yl)-methanoyl]propyl}-3-phenylpropionamide; chemical intermediates; for treating bacterial diseases | BAYER HEALTHCARE AG (DE) | 2009-06-09 | — | — | US | disclosed |
| US-7544709-B2 | Bactericides; (S)-3-(3-Butylureido)-N-{(S)-2-methyl-1-[1-((3R,4S)-4-methyl-2,5-dioxopyrrolidin-3-yl)-methanoyl]propyl}-3-phenylpropionamide; chemical intermediates; for treating bacterial diseases | BAYER HEALTHCARE AG (DE) | 2009-06-09 | — | — | US | disclosed |
| US-7544709-B2 | Bactericides; (S)-3-(3-Butylureido)-N-{(S)-2-methyl-1-[1-((3R,4S)-4-methyl-2,5-dioxopyrrolidin-3-yl)-methanoyl]propyl}-3-phenylpropionamide; chemical intermediates; for treating bacterial diseases | BAYER HEALTHCARE AG (DE) | 2009-06-09 | — | — | US | disclosed |
| US-7402683-B2 | 3-(1,3-benzodioxol-5-yl)-N-{(1S)-3-[((1S)-2-methyl-1-{[(3R,4S)-4-methyl-2,5-dioxo-3-pyrrolidinyl]carbonyl}propyl)amino]-3-oxo-1-phenylpropyl}-2-propenamide; bactericide, bacterial infection; septic infections, bone and joint infections, skin infections; veterinary medicine | BAYER HEALTHCARE AG (DE) | 2008-07-22 | — | — | US | disclosed |
| US-7402683-B2 | 3-(1,3-benzodioxol-5-yl)-N-{(1S)-3-[((1S)-2-methyl-1-{[(3R,4S)-4-methyl-2,5-dioxo-3-pyrrolidinyl]carbonyl}propyl)amino]-3-oxo-1-phenylpropyl}-2-propenamide; bactericide, bacterial infection; septic infections, bone and joint infections, skin infections; veterinary medicine | BAYER HEALTHCARE AG (DE) | 2008-07-22 | — | — | US | disclosed |
| US-7402683-B2 | 3-(1,3-benzodioxol-5-yl)-N-{(1S)-3-[((1S)-2-methyl-1-{[(3R,4S)-4-methyl-2,5-dioxo-3-pyrrolidinyl]carbonyl}propyl)amino]-3-oxo-1-phenylpropyl}-2-propenamide; bactericide, bacterial infection; septic infections, bone and joint infections, skin infections; veterinary medicine | BAYER HEALTHCARE AG (DE) | 2008-07-22 | — | — | US | disclosed |
| EP-1501795-B1 | CINNAMIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2007-02-28 | — | — | EP | disclosed |
| US-20060178369-A1 | Cinnamic acid amides | INTERMED DISCOVERY GMBH (DE) | 2006-08-10 | — | — | US | disclosed |
| US-20060173040-A1 | Arylamides | BAYER HEALTHCARE AG (DE) | 2006-08-03 | — | — | US | disclosed |
| EP-1448521-B1 | DERIVATIVES OF ANDRIMIDE AND MOIRAMIDE B HAVING ANTIBACTERIAL PROPERTIES | BAYER HEALTHCARE AG (DE) | 2005-09-28 | — | — | EP | disclosed |
| EP-1529042-A1 | ARYLAMIDES | Bayer HealthCare AG (DE) | 2005-05-11 | — | — | EP | disclosed |
| US-20050080129-A1 | Derivatives of andrimide and moiramide b having antibacterial properties | BAYER HEALTHCARE AG (DE) | 2005-04-14 | — | — | US | disclosed |
| EP-1501795-A1 | CINNAMIC ACID AMIDES | Bayer Aktiengesellschaft (DE) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004113290-A1 | SUBSTITUTED ALKYLAMIDES | BAYER HEALTHCARE AG (DE) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004020432-A1 | ARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2004-03-11 | — | — | WO | disclosed |
| WO-2003091212-A1 | CINNAMIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178369-A1 | Cinnamic acid amides | PIGS, NISCH, PIGO | CTSK 1258/4885CTSS 250/4885TRPA1 946/4885 |
| US-20090149528-A1 | Cinnamic acid amides | PIGS, NISCH, PIGO | CTSK 1258/4885CTSS 250/4885TRPA1 946/4885 |
| US-20060173040-A1 | Arylamides | AADAC, AHR, ARSA | CTSK 1367/4885CTSS 156/4885TRPA1 290/4885 |
| US-20050080129-A1 | Derivatives of andrimide and moiramide b having antibacterial properties | WEE1, MTX2, WEE2 | CTSK 1599/4885CTSS 1990/4885TRPA1 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.